Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) is moving into the commercial phase of its US FebriDx strategy after securing the regulatory clearance, distribution network and funding needed to pursue the outpatient healthcare market. oppurtunity
The US Food and Drug Administration granted FebriDx a Clinical Laboratory Improvement Amendments (CLIA) waiver in March 2026, allowing the test to be used at more than 300,000 US healthcare locations.
Consequently, Lumos estimates that about 80 million patients present with acute respiratory infections each year have access to the product.- equivalent to a market opportunity exceeding US$1 billion per year.
CLIA waiver broadens FebriDx market
FebriDx was in use at more than 170 healthcare locations across 24 states by the end of FY26.
A further rollout covering more than 30 urgent care sites has been secured, while three large urgent care groups with more than 230 sites are undertaking clinical and economic validation.
The immediate focus is on use of the test within those networks, reimbursement outcomes, repeat orders and the expansion of manufacturing capacity.
FebriDx is an instrument-free fingerstick blood test that measures the host-response biomarkers MxA and C-reactive protein. It provides a result in about 10 minutes to help clinicians distinguish bacterial infections from non-bacterial causes.
Bacterial and viral respiratory infections often present with similar symptoms, which can lead to antibiotics being prescribed when they are unlikely to help. FebriDx is designed to give clinicians more information during the consultation and support appropriate antibiotic use.
The test previously held FDA 510(k) clearance but was largely restricted to hospitals and moderate-complexity laboratories. The CLIA waiver extended its use to urgent care centres, primary care practices, community health services and retail clinics.
PHASE agreement provides US distribution channel
Lumos has an exclusive six-year agreement with PHASE Scientific to distribute FebriDx in the US. The agreement has a potential value of US$317 million, subject to PHASE meeting minimum order quantities and payment milestones. The figure is therefore not guaranteed revenue.
PHASE has sold more than 100 million rapid tests through its INDICAID product range and provides Lumos with an established national distribution channel. Lumos retains the manufacturing rights and intellectual property for FebriDx.
The CLIA waiver triggered a US$5 million prepayment from PHASE. In August 2026, Lumos received a US$767,800 purchase order to be shipped progressively through October. It is the first order linked to that prepayment and will be credited against the balance, while also contributing to PHASE’s minimum first-year commitment.
Further orders and the rate of product use by healthcare providers will indicate whether initial demand can be sustained beyond the prepayment period.
Urgent care rollout gathers pace
Lumos is targeting large urgent care groups, where an initial pilot can lead to a rollout across an established network.
WellStreet Urgent Care has become the company’s early reference account. A pilot that began at a busy Atlanta location expanded to 44 sites, with a pathway towards WellStreet’s full network of about 165 locations.
In July 2026, another regional operator agreed to deploy FebriDx across more than 30 sites handling an estimated 200,000 acute respiratory infection presentations annually. Three additional groups ranked among the top 10, top 25 and top 30 US urgent care operators are evaluating the test across networks totalling more than 230 sites.
Together, Lumos’s four priority accounts represent more than 430 potential locations and an internally estimated minimum of 2.6 million respiratory presentations a year.
The company classifies accounts across 4 stages: qualified opportunity, clinical and economic validation, network rollout and standardised adoption. The last stage involves incorporating FebriDx into standing orders, triage protocols, or routine clinical pathways.
Early reimbursement results
FebriDx has a dedicated US Proprietary Laboratory Analyses code, 0442U, and nationwide Medicare recognition at US$41.38 per test across all seven Medicare Administrative Contractor jurisdictions.
Lumos reported in May 2026 that more than 90% of reimbursement claims submitted to that point had been paid, with average payments above the Medicare benchmark.
Management cautioned that the sample was small and not statistically significant. More claims data will be needed to establish reimbursement performance across different sites, patient groups and private insurers.
FebriDx drives FY26 product revenue
Lumos reported revenue of US$11.1 million in FY24, US$12.4 million in FY25 and an unaudited US$13.2 million in FY26.
FebriDx revenue rose 875% to US$3.9 million in FY26, while Products division revenue increased 135% to US$4.3 million.
The company generated a US$2.7 million operating cash inflow in the June quarter and ended FY26 with US$15.4 million in cash. It subsequently repaid and closed its A$5 million secured loan facility and reported no debt.
The cash balance included proceeds from an A$20 million institutional placement, a share purchase plan and option exercises. The funds are supporting US commercialisation, working capital and an expansion of the Carlsbad manufacturing facility, which is expected to be completed in November 2026.
Lumos remained loss-making during the first half of FY26, recording an adjusted EBITDA loss of US$1.38 million and a net loss of US$4.88 million. Operating cash flow improved, although recent cash receipts have included regulatory milestone payments and the PHASE prepayment as well as product sales.
Services business broadens revenue base
Lumos also develops assays, readers and complete point-of-care systems for third parties through its Development Services and Contract Manufacturing division. Development projects can lead to follow-on manufacturing work if the products reach commercial production.
The division generated US$8.9 million in FY26 revenue, down 16% because an extended Hologic timeline reduced recognised intellectual-property licence revenue. Excluding that effect, project revenue rose 24% to US$7.5 million.
The largest program is with Hologic, where Lumos is helping develop a next-generation fetal fibronectin test used to assess the risk of preterm birth. The expanded agreement offers potential milestone payments of US$7 million to US$7.7 million. Assay feasibility work was expected to finish by the end of August 2026, while added assay, hardware and software work extended estimated overall completion to about June 2028.
Other projects include:
- Aptatek Biosciences awarded Lumos a US$1.5 million contract to advance the PheCheck at-home phenylketonuria monitoring system towards clinical trials and FDA submission.
- Micro-Pak signed a three-year contract manufacturing agreement for its Mold Analyzer system and placed an initial US$250,000 order.
- Lumos worked on 12 customer projects in the June 2026 quarter, including programs for Hologic, Micro-Pak, TeleMedVet and Aptatek.
The division reduces Lumos’s reliance on FebriDx, although revenue can move between reporting periods when major project timetables change. The delayed Hologic schedule affected services revenue in FY26.
Paediatric study and European distribution
BARDA has committed up to US$6.2 million to support a study of FebriDx in children aged 2–12 in CLIA-waived settings. By the end of FY26, Lumos had enrolled 250 patients, completed the seventh milestone and received cumulative payments of US$2.6 million under the program. Lumos plans to seek 510(k) clearance and a CLIA waiver for the younger age group if the study is successful.
Outside the US, Lumos is extending FebriDx distribution through partners. Alpha Medical has taken exclusive distribution rights in Romania and placed an initial stocking order, adding to arrangements covering the Baltic states and several markets served by Henry Schein, including the UK, Spain, Portugal and the Netherlands.
The US remains Lumos’s main commercial focus.
Next milestones
The forward plan for Lumos includes:
- Further PHASE purchase orders and the speed at which the remaining US$5 million prepayment is converted into shipped product.
- Reorder rates and test utilisation across the 44 WellStreet clinics, the new 30-site network and other active locations.
- Conversion of the three large urgent care validation programs into network-wide deployments.
- Larger reimbursement datasets across Medicare, Medicare Advantage, Medicaid and private payers.
- Manufacturing-capacity expansion at Carlsbad ahead of higher respiratory-season demand.
- The paediatric study and regulatory-pathway update expected towards the end of calendar 2026.
- Delivery against the revised Hologic timetable and conversion of other development projects into manufacturing contracts.
- Regulatory clearance and distribution are now in place for a broader US launch.
The next results will show whether Lumos can convert new sites into regular FebriDx users and build repeat product revenue while maintaining its contract development pipeline.